1. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007; 115:1285–1295. PMID:
17353456.
2. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Mowery J. Atherosclerosis. Potential targets for stabilization and regression. Circulation. 1992; 86(6 Suppl):III117–III123. PMID:
1424045.
3. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, Pelicci PG. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature. 1999; 402:309–313. PMID:
10580504.
Article
4. Francia P, delli Gatti C, Bachschmid M, Martin-Padura I, Savoia C, Migliaccio E, Pelicci PG, Schiavoni M, Lüscher TF, Volpe M, Cosentino F. Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation. 2004; 110:2889–2895. PMID:
15505103.
5. Camici GG, Schiavoni M, Francia P, Bachschmid M, Martin-Padura I, Hersberger M, Tanner FC, Pelicci P, Volpe M, Anversa P, Lüscher TF, Cosentino F. Genetic deletion of p66 (Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci U S A. 2007; 104:5217–5222. PMID:
17360381.
6. Napoli C, Martin-Padura I, de Nigris F, Giorgio M, Mansueto G, Somma P, Condorelli M, Sica G, De Rosa G, Pelicci P. Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. Proc Natl Acad Sci U S A. 2003; 100:2112–2116. PMID:
12571362.
Article
7. Kim CS, Kim YR, Naqvi A, Kumar S, Hoffman TA, Jung SB, Kumar A, Jeon BH, McNamara DM, Irani K. Homocysteine promotes human endothelial cell dysfunction via site-specific epigenetic regulation of p66shc. Cardiovasc Res. 2011; 92:466–475. PMID:
21933910.
Article
8. Kim YR, Kim CS, Naqvi A, Kumar A, Kumar S, Hoffman TA, Irani K. Epigenetic upregulation of p66shc mediates low-density lipoprotein cholesterol-induced endothelial cell dysfunction. Am J Physiol Heart Circ Physiol. 2012; 303:H189–H196. PMID:
22661506.
Article
9. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, Aoyama T. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986; 41:155–162. PMID:
2427760.
Article
10. Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron. 1993; 64:376–381. PMID:
8341382.
Article
11. Nakatsuka M, Asagiri K, Noguchi S, Habara T, Kudo T. Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts. Life Sci. 2000; 67:1243–1250. PMID:
10954057.
Article
12. Furukawa K, Iida T, Shiba H, Fujiwara Y, Uwagawa T, Shimada Y, Misawa T, Ohashi T, Yanaga K. Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model. Oncol Rep. 2010; 24:843–850. PMID:
20811662.
Article
13. Fujiwara Y, Furukawa K, Haruki K, Shimada Y, Iida T, Shiba H, Uwagawa T, Ohashi T, Yanaga K. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition. J Hepatobiliary Pancreat Sci. 2011; 18:731–739. PMID:
21484229.
Article
14. Choi S, Lee YR, Park MS, Joo HK, Cho EJ, Kim HS, Kim CS, Park JB, Irani K, Jeon BH. Histone deacetylases inhibitor trichostatin A modulates the extracellular release of APE1/Ref-1. Biochem Biophys Res Commun. 2013; 435:403–407. PMID:
23665318.
Article
15. Kim CS, Son SJ, Kim EK, Kim SN, Yoo DG, Kim HS, Ryoo SW, Lee SD, Irani K, Jeon BH. Apurinic/apyrimidinic endonuclease1/redox factor-1 inhibits monocyte adhesion in endothelial cells. Cardiovasc Res. 2006; 69:520–526. PMID:
16325162.
Article
16. Laviola L, Orlando MR, Incalza MA, Caccioppoli C, Melchiorre M, Leonardini A, Cignarelli A, Tortosa F, Labarbuta R, Martemucci S, Pacelli C, Cocco T, Perrini S, Natalicchio A, Giorgino F. TNFα signals via p66(Shc) to induce E-Selectin, promote leukocyte transmigration and enhance permeability in human endothelial cells. PLoS One. 2013; 8:e81930. PMID:
24349153.
Article
17. Tamura K, Manabe T, Imanishi K, Nonaka A, Asano N, Yamaki K, Tobe T. Effect of synthetic protease inhibitors on superoxide (O2-), hydrogen peroxide (H2O2) and hydroxyl radical production by human polymorphonuclear leukocytes. Hepatogastroenterology. 1992; 39:59–61. PMID:
1314767.
18. Yoon YS, Oh H, Kim Y, Lim SP, Kim CS, Kang MW. Nafamostat mesilate: can it be used as a conduit preserving agent in coronary artery bypass surgery? Korean J Thorac Cardiovasc Surg. 2013; 46:413–425. PMID:
24368967.
Article
19. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011; 286:44326–44335. PMID:
22030390.
Article
20. Yan W, Zhao K, Jiang Y, Huang Q, Wang J, Kan W, Wang S. Role of p38 MAPK in ICAM-1 expression of vascular endothelial cells induced by lipopolysaccharide. Shock. 2002; 17:433–438. PMID:
12022767.
Article
21. Kumar P, Miller AI, Polverini PJ. p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem. 2004; 279:43352–43360. PMID:
15292252.
22. Walker G, Langheinrich AC, Dennhauser E, Bohle RM, Dreyer T, Kreuzer J, Tillmanns H, Braun-Dullaeus RC, Haberbosch W. 3-deazaadenosine prevents adhesion molecule expression and atherosclerotic lesion formation in the aortas of C57BL/6J mice. Arterioscler Thromb Vasc Biol. 1999; 19:2673–2679. PMID:
10559010.
Article